CTLA4 and colorectal carcinoma: Similarly, while anti-CTLA-4 antibody partially suppressed tumor growth in both models, the combination of K3-SPG-ISV and CTLA-4 blockade showed marked tumor growth inhibition, where the synergistic effect was clear particularly in the CRC model (Supplementary Fig. 3).